ArticleMedicine2026
Relationship between C-reactive protein-to-albumin ratio and new-onset coronary artery disease and its severity in different glucose metabolic states: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The C-reactive protein-to-albumin ratio (CAR) integrates inflammatory and nutritional status.The study aimed to explore the potential connection between CAR and new-onset coronary artery disease (CAD) presence across varying glucose levels and to determine its correlation with the severity of coronary atherosclerosis. The retrospective cohort comprised 1489 individuals receiving coronary angiography for the first time. Using glycemic status criteria, the cohort was divided into 3 subgroups: normoglycemic (NGR, n = 255), prediabetic mellitus (Pre-DM, n = 617), and diabetic mellitus (DM, n = 618). CAR quartiles were analyzed for associations with CAD presence and Gensini score using multivariable logistic regression. And the predictive utility of the CAR for CAD was determined via analysis of the receiver operating characteristic curve. After multivariate adjustment, elevated CAR independently predicted new-onset CAD risk in the overall cohort. Stratified by glucose metabolism, the highest CAR quartile (Q4) significantly increased CAD risk in NGR (odds ratio [OR] = 4.25, P < .05) and DM (OR = 2.29, P < .05), while the association in Pre-DM attenuated post-adjustment. Critically, CAR robustly correlated with CAD severity in Pre-DM and DM, most pronounced in DM. CAR predicted CAD overall (area under the curve = 0.638, 95% confidence interval: 0.605-0.672), outperforming isolated CRP or albumin. CAR serves as an independent predictor for new-onset CAD and coronary lesion severity, with predictive efficacy modulated by glucose metabolic states. Its association with CAD risk is pronounced in NGR and DM, while Pre-DM exhibits attenuated significance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.